產品描述: | Dapagliflozin propanediol belongs to the class of orally administered antidiabetic agents designated as sodiumglucose cotransporter 2 (SGLT2) inhibitors |
靶點: |
SGLT2;SGLT |
體外研究: |
Dapagliflozin is a small-molecule inhibitor of SGLT2 that has been shown to be highly selective for SGLT2 compared with other SGLT family members and to have no off-target interactions in an in vitro screen of more than 330 receptors, enzymes, ion channels, and transporters |
體內研究: |
Dapagliflozin demonstrates good oral bioavailability, has a high volume of distribution, and has an in vivo metabolite profile that is qualitatively similar between preclinical species and humans. Both non-clinical and clinical assessments have shown dapagliflozin to have a highly favorable safety profile that is consistent with its simple mechanism of action, with no off-target effects observed |
動物實驗: |
Animal Models: Sprague-Dawley (SD) rats Dosages: 25, 100, 150, or 200 mg/kg Administration: oral |
參考文獻: |
1. Reilly TP, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014, 5(1):73-96. |
溶解性: |
Soluble in DMSO、Ethanol |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
1.988 ml |
9.941 ml |
19.881 ml |
5 mM |
0.398 ml |
1.988 ml |
3.976 ml |
10 mM |
0.199 ml |
0.994 ml |
1.988 ml |
50 mM |
0.04 ml |
0.199 ml |
0.398 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |